ArticleEBioMedicine2026
A multi-centre, phase 1a/1b dose escalation and expansion study of the HER2-directed antibody-drug conjugate T-Bren (BL-M07D1) in advanced breast cancer and other solid tumours.
Article in EBioMedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTrastuzumab brengitecan (T-Bren; BL-M07D1) is a HER2-directed antibody-drug conjugate (ADC) comprising a monoclonal antibody, a cathepsin B-cleavable linker, and a potent topoisomerase I inhibitor payload (Ed-04). We aimed to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumour activity of T-Bren in patients with advanced breast cancer and other solid tumours.
methodsThis phase 1 dose escalation and expansion study enrolled patients with inoperable locally advanced or metastatic breast cancer or other solid tumours pretreated with systemic therapy. Patients received intravenous T-Bren at doses ranging from 1.0 mg/kg on days 1 and 8 every 3 weeks (D1D8 Q3W) (accelerated titration), to 2.6 mg/kg, 3.2 mg/kg, 3.8 mg/kg, 4.4 mg/kg, 5.0 mg/kg, 5.6 mg/kg, 6.2 mg/kg on day 1 every 3 weeks (D1Q3W) (i3+3 design). Primary objectives were to assess dose-limiting toxicity/maximum tolerated dose (DLT/MTD), and establish the recommended phase 2 dose (RP2D).
findingsOverall, 253 patients were treated: DLTs occurred in two patients treated at 6.2 mg/kg Q3W, including grade 4 neutropenia with myelosuppression and grade 3 thrombocytopaenia in one patient, and grade 4 febrile neutropenia in another. In patients with breast cancer, ORR was 81.5% (66/81) in HER2-positive subgroup, 69.5% (57/82) in hormone receptor-positive/HER2-low disease, and 58.3% (14/24) in hormone receptor-negative/HER2-low disease. Median PFS was 18.2 months, 14.0 months, and 7.2 months in the HER2-positive, HR-positive/HER2-negative, and HR-negative/HER2-negative subgroups, respectively.
interpretationT-Bren demonstrated a manageable safety profile and clinically meaningful antitumour activity across a broad spectrum of HER2 expression in advanced breast cancer. The 4.4 mg/kg every three weeks regimen was established as the RP2D in breast cancer.
fundingThis study was funded by the sponsor Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.